Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer - PubMed
3 hours ago
- #NSCLC Genomics
- #MET Exon 14 Skipping
- #TKI Resistance
- MET exon 14 skipping mutations (METΔex14) in NSCLC have a prevalence of 1.02%, and are more common in sarcomatoid histology.
- Common concurrent alterations with METΔex14 include TP53, CDK4, and EGFR mutations; MET amplification and cell cycle pathway changes link to worse crizotinib outcomes.
- Resistance to MET inhibitors often arises from MET D1228X/Y1230X mutations or off-target alterations in RTK/RAS/MAPK and PI3K/AKT/mTOR pathways.
- METΔex14 can emerge as a resistance mechanism after EGFR or ALK inhibitors, indicating a need for tailored therapies to address genomic complexity.